Tonix Pharmaceuticals (TNXP)
NASDAQ:TNXP
Want to see TNXP full AI Analyst Report?
TNXP Stock Chart & Stats
$15.08
-$0.02(-7.15%)
At close: 4:00 PM EST
$15.08
-$0.02(-7.15%)
Day’s Range― - ―
52-Week Range$11.60 - $69.97
Previous CloseN/A
Volume36.66M
Average Volume (3M)416.81K
Market Cap
$201.49M
Enterprise Value$17.31M
Total Cash (Recent Filing)$185.47M
Total Debt (Recent Filing)$1.29M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 10, 2026EPS Estimate
-2.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.66
Shares Outstanding15,940,801
10 Day Avg. Volume494,838
30 Day Avg. Volume416,807
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.99
Enterprise Value/Gross Profit1.87
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$41.33Price Target Upside174.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.93
Revenue Forecast (FY)$30.05M
Bulls Say, Bears Say
Bulls Say
Payer Coverage ExpansionBroad commercial and Medicaid formulary inclusion materially improves durable patient access and prescription volume potential for TONMYA. Persistent payer coverage reduces barriers to adoption, supports predictable revenue scaling over multiple quarters, and strengthens competitive positioning in its therapeutic category.
Phase 3 Fibromyalgia EfficacyRobust Phase 3 clinical efficacy with favorable benefit-risk metrics creates lasting commercial and regulatory advantages. Clear clinical differentiation supports prescriber confidence, formulary negotiations, and longer-term uptake, reducing execution risk for commercialization and underpinning recurring prescription demand.
Improving Revenue And Gross MarginSustained revenue growth with meaningful gross margin expansion indicates early operating leverage and the potential to better absorb fixed R&D and commercial costs. If maintained, this trend supports a pathway to narrower losses and improved cash conversion over the medium term.
Bears Say
High Cash BurnMaterial negative operating and free cash flow denote sustained funding needs that will persist until revenue scales or costs compress. High burn increases dependence on external capital, creates dilution risk, and can constrain the company’s ability to fund late-stage trials or commercial expansion without additional financing.
Large Net Losses & Negative MarginsExtremely negative net margins and large losses reflect that current revenues are far from covering operating expenses. Persisting at scale, such losses undermine returns on equity, limit reinvestment capacity, and prolong the timeline to self-sustaining profitability absent marked revenue growth or structural cost reductions.
Reliance On External FinancingAs a clinical-stage firm without consistent marketed-product revenue, Tonix remains structurally dependent on capital markets, partnerships, or licensing to fund development and commercialization. This reliance increases vulnerability to market volatility and can delay programs if access to non-dilutive capital is limited.
Tonix Pharma News
TNXP FAQ
What was Tonix Pharmaceuticals’s price range in the past 12 months?
Tonix Pharmaceuticals lowest stock price was $11.60 and its highest was $69.97 in the past 12 months.
What is Tonix Pharmaceuticals’s market cap?
Tonix Pharmaceuticals’s market cap is $201.49M.
When is Tonix Pharmaceuticals’s upcoming earnings report date?
Tonix Pharmaceuticals’s upcoming earnings report date is Aug 10, 2026 which is in 71 days.
How were Tonix Pharmaceuticals’s earnings last quarter?
Tonix Pharmaceuticals released its earnings results on May 11, 2026. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$2.57 by -$0.36.
Is Tonix Pharmaceuticals overvalued?
According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Undervalued.
Does Tonix Pharmaceuticals pay dividends?
Tonix Pharmaceuticals does not currently pay dividends.
What is Tonix Pharmaceuticals’s EPS estimate?
Tonix Pharmaceuticals’s EPS estimate is -2.55.
How many shares outstanding does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 15,940,801 shares outstanding.
What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?
Tonix Pharmaceuticals reported an EPS of -$2.93 in its last earnings report, missing expectations of -$2.57. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Tonix Pharmaceuticals?
Currently, no hedge funds are holding shares in TNXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.33 (174.09% Upside)
$41.33 (174.09% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $286.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.65%
12-Months-Change
Fundamentals
Return on Equity
-67.65%
Trailing 12-Months
Asset Growth
33.72%
Trailing 12-Months
Company Description
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
TNXP Stock 12 Month Forecast
Average Price Target
$41.33
▲(174.09% Upside)
Technical Analysis
Ownership Overview
0.15% Insiders
6.13% Mutual Funds
3.41% Other Institutional Investors
82.98% Public Companies and
Individual Investors